Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AUC of TYMS for predicting the efficacy of chemotherapy on colon cancer was 0.831 (95% CI, 0.735-0.926), and both had higher predictive values.
|
31423175 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tumor TS levels were prospectively evaluated in two adjuvant therapy trials for patients with resected stage II or III colon cancer.
|
27821793 |
2017 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression.
|
29088787 |
2017 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrated for the first time, that human TS and DHFR form a strong complex in vitro and co-localize in human normal and colon cancer cell cytoplasm and nucleus.
|
27187663 |
2017 |
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thymidylate synthase polymorphism in Mexican patients with colon cancer treated with 5-fluorouracil.
|
27685916 |
2017 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
EMAST was more frequent in colon cancer than rectal cancer (p=0.033), and associated with MSI-H phenotype (p<0.001), low expression of hMSH3 (p=0.004), and overexpression of thymidylate synthase (p=0.006).
|
27889996 |
2016 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that the enhanced HSP90 function and subsequent activation of Src induce expression of TYMS and acquired resistance to 5-FU in colon cancer.
|
26416450 |
2015 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Regulation of TS by irinotecan was evaluated by western blotting and quantitative real-time PCR assay. dMMR accounted for 18.5 % and was related with proximal colon cancer (p = 0.005), poorly differentiated tumors (p = 0.018) and favorable efficacy with a higher disease control rate (DCR), a longer progression-free survival (PFS) and a trend of longer overall survival (OS). dMMR colon cancer cells were more sensitive to irinotecan.
|
26142736 |
2015 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, AQP5 and P-glycoprotein (P-gp), glutathione S-transferase-π (GST-π), topoisomerase II (TOPO II), and thymidylate synthase (TS) were checked in CC and adjacent cancer tissues; AQP5-siRNA was applied to silencing AQP5 in CC cell line HT-29, 5-fluorouracil (5-FU), and cisplatin (DDP) added on cells, and sulforhodamine B (SRB) was used; fluorescence real-time quantitative RT-PCR and Western blot were employed to detect changes in multidrug resistance factor and expression mitogen-activated protein kinase (MAPK) signaling pathway in HT-29.
|
24752576 |
2014 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Arsenic trioxide (ATO) has been shown to suppress TYMS in a colonic cancer model.
|
24691991 |
2014 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These features include cellular morphology, expression of colon cancer stem cell markers, expression of survivin and thymidylate synthase and sensitivity to fluorouracil.
|
23674327 |
2013 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
High TS was only found in 9.3% of rectal tumors, but in 29.7% of colon cancers (p=0.0042).
|
23968134 |
2013 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study evaluates if a combined analysis of MMR status and TS expression in colon cancer can add prognostic value and better predict response to adjuvant 5-FU-based chemotherapy.
|
23276521 |
2013 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously shown that miR-215 suppressed the expression of key targets such as thymidylate synthase (TS), dihydrofolate reductase, and denticleless protein homolog (DTL) in colon cancer. miR-215 is a tumor suppressor candidate due to the upregulation of p53 and p21 by targeting DTL.
|
21752725 |
2011 |
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
|
21630057 |
2011 |
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
|
20966539 |
2010 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we demonstrate that the histone deacetylase inhibitors (HDACi) vorinostat and LBH589 significantly downregulate TS gene expression in a panel of colon cancer cell lines.
|
19384949 |
2009 |
Malignant tumor of colon
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer.
|
18203297 |
2008 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
|
19105824 |
2008 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
In both gastric and colon cancers, thymidylate synthase and orotate phosphoribosyltransferase mRNA expressions were higher (p < 0.0001, p <0.0001 respectively in gastric cancer and P = 0.0002, p < 0.0001 respectively in colon cancer) and dihydropyrimidine dehydrogenase mRNA expressions were lower in cancer cells than in cancerous stroma (P = 0.0136 in gastric cancer and p < 0.0001 in colon cancer).
|
18652704 |
2008 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
'High-expression' variants of TS 2R/3R repeat, TS enhancer region 3R G/C, TS 1494del6 bp, and TS haplotype analysis might help to identify stage II and stage III colon cancer patients who are at great risk of developing tumor recurrence, and also those who are more likely to benefit from 5-fluorouracil-based adjuvant chemotherapy.
|
18192902 |
2008 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the reduction of TS expression resulted in enhancement of the sensitivity to 5-FU in human colon cancer DLD-1 cells.
|
18425338 |
2008 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study investigated the predictive role of TS at the DNA and protein levels in patients with N(+) colon cancer (n = 38).
|
18661526 |
2008 |
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival.
|
17290389 |
2007 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, a comprehensive gene expression analysis at the levels of both transcriptional and post-transcriptional regulation was conducted to identify response markers using human genome array with TS-depleted human colon cancer HCT-C18 (TS-) cells and HCT-C18 (TS+) cells stably transfected with the human TS cDNA expression plasmid.
|
16584549 |
2006 |